NIFTY 50

Aurobindo Pharma Q4FY20 earnings today: Here are key expectations

Updated : June 03, 2020 09:26 AM IST

Aurobindo Pharma will be releasing its Q4FY20 numbers on Wednesday. While earnings are important, the majority of the triggers are already in place for Aurobindo Pharma.

The revenue is expected to grow around 11 percent, margins are expected to be stable at 20 percent and profit growth of around 16 percent will be aided by a high base. US business is expected to grow around marginally and Europe and the rest of the world are probably expected to grow around 5-7 percent.

Here's a list of key expectations:


Q4FY20 (YoY)
  • Revenue seen (GU)11.1% at Rs 5,880.8 crore vs Rs 5,292.2 crore
  • EBITDA seen (GU)12% at Rs 1,183.54 crore vs Rs 1,057.5 crore
  • Margins seen flat at 20.1% vs 20%
  • Profit seen (GU)16% at Rs 677.84 crore vs Rs 585.4 crore
Q4FY20: Key Expectations
  • Growth expected to slow YoY due to high base
  • Fewer new drug approvals reduce YoY growth trajectory of US biz
  • US biz expected to grow marginally at around $423 m
  • Expect Europe & Rest of World to grow around 5% to 7%
  • Street mixed with est of growth to slight decline for Antiretroviral drug
  • Margins estimated to be in the range of 19-20%
Q4FY20: Commentary To Watch
  • Pending regulatory issues
  • Inorganic growth opportunities
  • US growth outlook post-Sandoz deal
  • Ramp-up of sales from Unit 4 which has received a Voluntary Action Indicated status
  • Debt outlook
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV